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N. Groot,1 D. Shaikhani,2 Y. K. O. Teng,3 K. de Leeuw,4 M. Bijl,5 R. J. E. M. Dolhain,6 E. Zirkzee,7 R. Fritsch-Stork,8  
I. E. M. Bultink,9  and S. Kamphuis2
Objective. Childhood- onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune 
disease. Long- term outcome data are limited. This study was undertaken to identify clinical characteristics and 
health- related quality of life (HRQoL) of adults with childhood- onset SLE.
Methods. Patients participated in a single study visit comprising a structured history and physical examination. 
Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI- 2K]), damage (scored using the System-
ic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL 
(scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed.
Results. In total, 111 childhood- onset SLE patients were included; the median disease duration was 20 years, 
91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI- 2K score 4), and 71% 
of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease- modifying antirheumatic drugs. 
The vast majority of new childhood- onset SLE–related manifestations developed within 2 years of diagnosis. Damage 
such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predom-
inantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, 
replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 
years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual 
was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, 
P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 
0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence 
of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI- 2K score ≥8) and changes in physical 
appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively).
Conclusion. The majority of adults with childhood- onset SLE in this large cohort developed significant damage 
at a young age and had impaired HRQoL without achieving drug- free remission, illustrating the substantial impact of 
childhood- onset SLE on future life.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a lifelong, mul­
tisystem autoimmune disease, known for its highly het­
erogeneous clinical presentation and waxing–waning disease 
course. Childhood­ onset SLE, defined as SLE with onset at 
age <18 years (1), represents 10–20% of all SLE cases and 
has a mean age at onset of 11–12 years (2,3). Childhood­ 
onset SLE is a rare disease, with an incidence rate of 0.3–0.9 
per 100,000 patient­ years and a prevalence of 1.89–25.7 per 
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100,000 children worldwide (4–6). Similar to SLE in adults, 
childhood­ onset SLE is seen more often in nonwhite individu­
als and girls (female:male ratio 4–5:1). Disease manifestations 
differ among ethnicities, but clinical outcomes such as disease 
activity and damage tend to be similar among patients when 
data are corrected for socioeconomic status (7–10).
Although survival rates for childhood­ onset SLE patients 
have greatly improved, morbidity is still high, and questions 
from children and parents regarding the future course of the dis­
ease are difficult to answer (7,11). Long­ term follow­ up studies 
of childhood­ onset SLE are limited and often have low patient 
numbers and/or include patients with relatively short disease 
duration; thus, detailed evidence regarding development of new 
organ involvement and damage over time is lacking (7,12–17). 
Overall, these studies show that the majority of adolescents and 
young adults with childhood­ onset SLE still have active disease, 
receive immunosuppressive drugs, and steadily accrue damage 
during their disease (7,11,12,18,19).
Only 1 North American cohort study of both childhood­ 
onset SLE and adult­ onset SLE patients has included a large 
number of childhood­ onset SLE patients (n = 90) with a long 
disease duration (mean 16.5 years) and compared outcomes 
of the 2 diseases (18). In that study, structured telephone 
interviews were used to collect patient­ reported clinical out­
comes, of which only significant renal outcomes could be 
validated by chart review. At the time of interview, childhood­ 
onset SLE patients had lower disease activity and were more 
likely to have ever received and currently receive glucocorti­
coids and disease­ modifying antirheumatic drugs (DMARDs) 
when compared to adult­ onset SLE patients (18). This was 
also observed in a cohort in which outcomes were compared 
between childhood­ onset SLE patients, adult­ onset SLE 
patients, and late­ onset SLE patients with a disease duration 
of 12 years (19). In the North American cohort of adult­ onset 
and childhood­ onset SLE patients, the latter was shown to be 
an independent risk factor for mortality (11). Due to the nature 
of that cohort study (which relied primarily on patient­ reported 
clinical outcomes), data regarding development of damage 
could not be included.
In children with childhood­ onset SLE, health­ related qual­
ity of life (HRQoL) has been shown to be impaired compared 
to healthy peers, which has been at least partially attributed to 
disease activity and damage (20,21). There were no data avail­
able regarding HRQoL in adult patients with childhood­ onset 
SLE or pertaining to the specific factors that could influence 
HRQoL in these patients.
In the present study (the Childhood­ Onset SLE in The Neth­
erlands [CHILL­ NL] study), we aimed to assess the disease bur­
den of childhood­ onset SLE in The Netherlands. In this report, we 
describe the clinical characteristics of adults with childhood­ onset 
SLE, focusing on disease course and damage accrual over time, 
in association with HRQoL.
PATIENTS AND METHODS
Patients. All childhood­ onset SLE patients who were 
>18 years old, had been treated in any Dutch hospital, and 
met the American College of Rheumatology (ACR) criteria for 
SLE (22,23) were eligible for inclusion in the CHILL­ NL study. 
Rheumatologists, immunologists, nephrologists, hematolo­
gists, and neurologists in all 88 Dutch hospitals were con­
tacted. Private practices were not contacted, as there are 
very few in The Netherlands. Moreover, as SLE is a systemic 
disease and hospital diagnostics are essential for optimal 
treatment, rheumatologists in private practices do not typi­
cally treat SLE patients. All medical specialists in secondary or 
tertiary hospitals were contacted via email and informational 
flyers. They were asked to identify SLE patients in their care 
who were diagnosed as having childhood­ onset SLE prior to 
their 18th birthday, and to ask if these patients were inter­
ested in participating in a study on long­ term outcomes. The 
study was also promoted by the Dutch SLE patient organiza­
tion (the National Association for Lupus, APS, Scleroderma, 
and MCTD [NVLE]) both in their magazine and on their web 
site (24). Due to the study design, data regarding mortality in 
childhood­ onset SLE or clinical characteristics of deceased 
patients could not be retrieved reliably; therefore, we only 
report data on surviving patients. The Research Ethics Board 
of the Erasmus University Medical Center approved the study 
(MEC­ 2013­ 163), and written informed consent was obtained 
from all patients.
Data collection. The CHILL­ NL team designed the 
study with the help of a patient panel (n = 5). Patients were 
seen for a single 1.5­ hour study visit at the Erasmus University 
Medical Center. If patients were unable to travel, the study visit 
was performed at the hospital of their choice. During the study 
visit, an extensive medical history was obtained using struc­
tured data collection forms and (validated) questionnaires. 
Data regarding demographics, current health, disease activity, 
damage, disease onset and progression over time, and current 
and previous medication use were collected. A physical exam­
ination was performed, blood and urine were collected, and 
patients completed questionnaires regarding HRQoL, effects 
of medication use (on physical appearance, physical health, or 
mental health [with a yes/no option and a request for elabora­
tion]), education and employment, fertility and family planning, 
fatigue, depression, and coping and resilience (25–30). For 
this report, a selection of the data (i.e., disease activity, med­
ication use, disease manifestations over time, damage, and 
HRQoL) was used. Medical information was requested from all 
hospitals where patients had previously received care. Clinical 
data collected during the study visit were supplemented and 
verified through the retrieved medical history. Only data that 
could be verified in medical records were reported.
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Demographics. Data regarding demographic character­
istics such as age, sex, self­ reported ethnicity, and area of res­
idence were collected by structured questionnaires. Categories 
of ethnicity included African/Caribbean, Arabic, Asian, Hispanic, 
white, and mixed.
Diagnosis, disease manifestations, and damage over 
time. Data on which components of ACR SLE criteria and/or SLE 
International Collaborating Clinics (SLICC) SLE criteria patients met 
were recorded, in addition to any childhood­ onset SLE–related 
manifestations at diagnosis (22,23,31). Definitions of disease man­
ifestations are described in Figure 1. Disease duration was defined 
as years between date of diagnosis (as reported in medical records) 
and study visit. Based on findings in previous studies, disease 
manifestations of childhood­ onset SLE over time were recorded 
according to 6 predefined time frames: 1) never, 2) prior to diag­
nosis, 3) at diagnosis, 4) <2 years since diagnosis, 5) 2–5 years 
since diagnosis, and 6) >5 years since diagnosis (7,32,33). Age 
at first myocardial infarction, renal transplantation, cerebrovascu­
lar accident (CVA), and/or replacement arthroplasty was obtained 
from medical records. Specific disease manifestations such as 
antibody positivity were recorded as positive or negative if found in 
medical records and as unknown if not mentioned in the records. 
Nephrotic syndrome was recorded as present if clinical manifes­
tations (edema, proteinuria [3–3.5 gm/24 hours], and hypoalbu­
minemia [<25 gm/liter]) were present, or if medical records included 
a nephrotic syndrome diagnosis. Hypertension was recorded as 
present if blood pressure was >140/90 mm Hg on repeated exam­
inations, or if medical records included a hypertension diagnosis.
Disease activity and medication use. Disease  activity 
was assessed using the SLE Disease Activity Index 2000 
( SLEDAI­ 2K) (34). High disease activity was defined by a 
 SLEDAI­ 2K score of ≥8 (35,36). Additionally, patients were asked 
to rate their disease activity on a visual analog scale (VAS), rang­
ing from 0 (no disease activity) to 100 (very high disease activ­
ity). Medication use was classified as current use, previous use, 
and never used. Glucocorticoids and hydroxychloroquine (HCQ) 
were considered separately. Non­ HCQ DMARDs included aza­
thioprine, cyclosporine, cyclophosphamide, leflunomide, meth­
otrexate, mycophenolate mofetil, rituximab, and tacrolimus. All 
other medication use, including antiepileptic medication, antihy­
pertensive drugs such as angiotensin­ converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers (ARBs), and cou­
marins was also recorded. During the study visit, patients were 
asked if there were any medications that had affected them in 
terms of their physical appearance, physical health, or mental 
health, and in what ways they were affected.
Figure  1. First occurrence of disease manifestations (by organ system) over time since diagnosis of childhood­ onset systemic lupus 
erythematosus (SLE). Skin category includes malar rash, discoid rash, ulcers, photosensitivity, cutaneous vasculitis, and other ongoing 
inflammatory SLE­ related rashes. Musculoskeletal category includes arthritis and myositis. Hematologic category includes hemolytic anemia, 
thrombocytopenia, leukopenia, lymphopenia, neutropenia, and thrombotic thrombocytopenic purpura. Renal category includes persistent 
proteinuria and lupus nephritis. Cardiovascular category includes pericarditis, myocarditis, endocarditis, myocardial infarction, angina pectoris, 
cerebrovascular accident, transient ischemic attack, arterial thrombosis, venous thrombosis, and embolus. Central nervous system category 
includes aseptic meningitis, cerebrovascular disease, demyelinating disease, lupus headache, myelopathy, chorea, convulsions, acute 
confusional state, anxiety disorder, mood disorder, and psychosis. Pulmonary category includes pleuritis, pneumonia, fibrosis, shrinking lung, 
pulmonary arterial hypertension, and interstitial lung disease. Peripheral nervous system category includes autonomous nervous system disorder, 
mononeuropathy, myasthenia gravis, Guillain­ Barré syndrome, cranial nerve neuropathy, plexopathy, and polyneuropathy. Gastrointestinal 
category includes peritonitis, pancreatitis, autoimmune hepatitis, and liver cirrhosis.
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Damage assessment. Disease damage was assessed 
using the SLICC/ACR Damage Index (SDI) (37). Presence of dam­
age was defined by an SDI score of ≥1. For damage that had a 
specific temporal component (i.e., cognitive impairment or renal 
impairment present for ≥6 months), it was recorded if the item was 
found in 2 consecutive reports from the medical records.
Assessment of health- related quality of life. HRQoL 
was assessed using the Short Form 36 (SF­ 36), which includes 
36 questions about 8 health domains: physical functioning, social 
functioning, role limitations due to physical problems, role limi­
tations due to emotional problems, mental health, vitality, bodily 
pain, and general health perception (25). Patient HRQoL scores 
were compared to those from the general population in The 
Netherlands. Effects on HRQoL from the following factors were 
assessed: disease activity (low [SLEDAI­ 2K score ≤4], intermedi­
ate [5–7], or high [≥8]) (35), SLEDAI­ 2K items concerning changes 
in physical appearance (i.e., ongoing inflammatory rash and/or 
alopecia), and damage.
Statistical analysis. Group comparisons were made using 
the Mann­ Whitney U test or the Kruskal­ Wallis test, where appli­
cable. One­ sample t­ tests were used for comparisons with nor­
mative data from the Dutch population. Logistic regression anal­
ysis was performed to assess associations of individual variables 
and the development of damage. Selection of these variables 
was based on a literature review (38). Presence of damage was 
defined as the outcome of interest, and predetermined variables 
were covariates in the model. Variables with an individual P value 
of <0.1 were used to build the multivariable model, using a hierar­
chical entry method. In the final, most parsimonious model, var­
iables with associations at a P value of <0.05 were considered 
to contribute. To assess goodness of fit, the Hosmer­ Lemeshow 
test was used, and residual statistics (i.e., Cook’s distance for 
standardized residuals, deviance, and leverage) were analyzed. All 
analyses were performed using IBM SPSS Statistics version 22.
RESULTS
Patient inclusion. Patients were enrolled in the 
CHILL­ NL study from November 2013 until April 2016. Eighty­ 
eight secondary and tertiary hospitals were contacted. Doc­
tors from 18 hospitals confirmed having adult patients with 
childhood­ onset SLE under their care and sent contact infor­
mation for 121 patients to the study team. An additional 15 
patients contacted the study team via NVLE. Of these 136 
patients, 111 patients (82%) were seen for a single study visit 
(see Supplementary Figure 1, on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40697/abstract). Most study participants (69%) were 
treated in a tertiary center (Supplementary Figure 1). As an 
example of the proportion of patients treated at a certain site 
who participated in the study, 17 of the 23 current patients 
with childhood­ onset SLE (74%) at the Erasmus University 
Medical Center participated in the CHILL­ NL study. Forty per­
cent of patients in the study lived within the vicinity of the Eras­
mus University Medical Center; residences of the remaining 
patients were equally distributed over the rest of the country.
Demographic and disease characteristics of the 
patients. The median age at study visit was 33 years, with a 
median disease duration of 20 years (Table 1). Patients were 
divided into 3 diagnostic eras according to year of diagno­
sis, which ranged from 1959 to 2013. The number of patients 
among the 3 groups was evenly distributed, with 33% of 
patients diagnosed before 1990. The most common elements 
of the ACR criteria met by patients at diagnosis were anti­
nuclear antibody positivity, immunologic features, and arthri­
tis (see Supplementary Figure 2, http://onlinelibrary.wiley.
com/doi/10.1002/art.40697/abstract). Almost all participants 
were female (91%). The majority of patients were white (72%), 
while 10% were African/Caribbean, 7% Asian, 3% Hispanic, 
1% Arabic, and 7% of mixed heritage. Due to the majority of 
patients being white, ethnicity was presented as a binary cat­
egory: white and nonwhite. Age at onset and disease duration 
were similar across these ethnic groups.
Treatment. The vast majority of patients (68%) were 
taking glucocorticoids and/or non­ HCQ DMARDs at the time 
of the study visit (Table 1). Fifty­ six patients (51%) were taking 
glucocorticoids (with or without non­ HCQ DMARDs), and 76 
patients (68%) were taking HCQ (of whom 29% were being 
treated with HCQ monotherapy). Sixty­ five percent of patients 
were taking other non­ antiinflammatory medications, includ­
ing antihypertensive drugs (such as ACE inhibitors and ARBs) 
(51%), statins (14%), coumarins (14%), acetylsalicylic acid 
(12%), antidepressants (8%), antiepileptic drugs (5%), and 
erythropoietin (5%). When asked about the effects of medi­
cation use on physical appearance, physical health, or men­
tal health, the majority of patients reported negative effects. 
The largest impact reported was physical appearance (89% of 
patients), which was perceived negatively by 93% of patients. 
Patients also reported a negative impact on physical health 
(36%) and mental health (28%). Effects on physical appear­
ance (e.g., weight gain) and on mental health (e.g., mood 
swings) were mostly attributed to prednisone use. Effects on 
physical health (e.g., nausea) were mostly attributed to non­ 
HCQ DMARDs.
Disease activity. At the study visit, recorded disease 
activity was relatively low (median SLEDAI­ 2K score 4 and 
median VAS score 13). Low complement levels (32%), skin 
rashes (14%), and proteinuria (13%) were the most commonly 
recorded SLEDAI­ 2K items. No difference was found between 
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the SLEDAI­ 2K scores of patients receiving glucocorticoids and/
or non­ HCQ DMARDs, patients receiving HCQ monotherapy, 
and patients not receiving glucocorticoids, non­ HCQ DMARDs, 
or HCQ monotherapy (P = 0.177 by Kruskal­ Wallis test).
Infections. During their disease course, almost half of the 
patients (45%) had been admitted to the hospital due to infec­
tions that required intravenous antibiotic therapy. Forty­ eight per­
cent of these patients were admitted more than once (Table 1).
Disease manifestations and damage over time. 
The organ systems that were most frequently involved were the 
skin (e.g., malar or discoid rash, cutaneous vasculitis), muscu­
loskeletal system (primarily arthritis), hematologic system (e.g., 
hemolytic anemia, leukopenia), and renal system (e.g., lupus 
nephritis). The vast majority of new manifestations in these organ 
systems developed within 2 years of diagnosis (Figure 1). Cardi­
ovascular, pulmonary, and central nervous system (CNS) man­
ifestations occurred in the short term and long term. Within 2 
years of diagnosis, pericarditis, pleuritis, and epilepsy were the 
most common manifestations within these organ systems, while 
5 years after diagnosis damage was most prevalent (e.g., myo­
cardial infarction and CVA). Manifestations in the peripheral nerv­
ous system and gastrointestinal system were uncommon and 
mainly occurred ≥5 years after diagnosis.
Disease damage. Renal, neuropsychiatric, and muscu­
loskeletal damage were the most prevalent types of damage 
 (Figure  2A). In total, 62% percent of patients had developed 
disease damage, and the percentage of patients with damage 
increased over time (Figure 2B). Musculoskeletal damage (e.g., 
avascular necrosis, deforming/erosive arthritis), neuropsychiat­
ric damage (primarily cognitive impairment, often combined with 
seizures requiring treatment of >6 months), and renal damage 
(e.g., end­ stage renal disease) were the most prevalent types of 
damage across disease duration categories (Figure 2C and Sup­
plementary Table 1, http://onlinelibrary.wiley.com/doi/10.1002/
art.40697/abstract).
Notably, after 10–20 years, when childhood­ onset SLE 
patients were in their 20s and 30s, more than half experienced 
significant damage (Figure  2C, and Supplementary Table 1). 
Seven childhood­ onset SLE patients (5%) experienced a CVA 
(at a median age of 20 years). Sixteen patients (24%) who had 
renal involvement during their disease subsequently developed 
damage (Supplementary Table 2, http://onlinelibrary.wiley.com/
doi/10.1002/art.40697/abstract). Of these 16 patients, 38% 
received a renal transplant (median age 24 years), and 1 patient 
was undergoing dialysis. Six patients underwent replacement 
arthroplasty in 1 joint, and 4 patients received >1 joint replace­
ment; the median age at first joint replacement was 34 years 
(Supplementary Table 2). Five patients experienced a myocardial 
infarction (at a median age of 39 years), and 3 of them under­
went coronary bypass surgery.
Factors related to the development of damage. 
Logistic regression analysis was performed, and odds ratios 
(ORs) and 95% confidence intervals (95% CIs) were calcu­
Table 1. Patient characteristics at the study visit* 
Female 101 (91)
Ethnicity
White 80 (72)
Nonwhite 31 (28)
Age at diagnosis, median (range) years 14 (4–17)
Age at study visit, median (range) years 33 (18–65)
Disease duration, median (range) years 20 (1–55)
Era of diagnosis
Prior to 1990 37 (33)
Between 1990 and 2000 38 (34)
After 2000 36 (32)
Disease activity
SLEDAI- 2K, median (range) score 4 (0–16)
SLEDAI ≤4 72 (65)
SLEDAI 5–7 23 (21)
SLEDAI ≥8 16 (14)
Patient-reported VAS, median (range) score 13 (0–95)
Current glucocorticoids/non- HCQ DMARDs 
use†‡
75 (68)
Glucocorticoids with non- HCQ DMARDs 40 (53)
Glucocorticoids only 16 (21)
Non- HCQ DMARDs only 15 (20)
2 non- HCQ DMARDs with or without  
glucocorticoids
4 (5)
Current HCQ use‡ 76 (68)
HCQ with non- HCQ DMARDs/glucocorticoids 54 (71)
HCQ monotherapy 22 (29)
No HCQ, glucocorticoids, or non- HCQ 
DMARDs
14 (13)§
SDI, median (range) 1 (0–8)
SDI ≥1 69 (62)
Infections requiring IV antibiotics (ever)‡ 50 (45)
1 occurrence 26 (52)
>1 occurrence 24 (48)
* Except where indicated otherwise, values are the number (%) 
of patients. SLEDAI- 2K = Systemic Lupus Erythematosus Disease 
Activity Index 2000; VAS = visual analog scale; HCQ = hydroxychlo-
roquine; SDI = Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index. 
† More information regarding specific disease- modifying antirheu-
matic drug (DMARD) use can be found in Supplementary Table 
3, on the Arthritis & Rheumatology web site at http://onlinelibrary. 
wiley.com/doi/10.1002/art.40697/abstract. 
‡ Percentages below are based on the number of patients receiv-
ing the treatment (n = 75 or 76) or the number of patients with 
infections requiring intravenous (IV) antibiotics (n = 50), rather than 
the full cohort of 111 patients. 
§ More information regarding these 14 patients can be found in 
Supplementary Table 4. 
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lated to assess associations between individual variables and 
development of damage (Table  2). The univariate analysis 
showed longer disease duration; additionally, antiphospholipid 
antibody (aPL) positivity, infections requiring hospitalization 
(ever), the presence of hypertension (ever), and the presence 
of nephrotic syndrome (ever) were associated with the pres­
ence of damage. Neither sex nor ethnicity showed a signifi­
cant association with the presence of damage. Current HCQ 
monotherapy was associated with the absence of damage. In 
the multivariate analysis, disease duration (OR 1.147 [95% CI 
1.077–1.227], P < 0.001), hypertension (OR 3.214 [95% CI 
1.040–9.932], P = 0.043), and aPL positivity (OR 3.559 [95% 
CI 1.161–10.908], P = 0.026) were significantly associated 
with presence of damage, and current HCQ monotherapy (OR 
0.162 [95% CI 0.042–0.633], P = 0.009) was again associated 
with the absence of damage. No differences in number or type 
of organ systems involved or in antiinflammatory medication 
use were found between patients currently receiving HCQ 
monotherapy and other patients.
Health- related quality of life. HRQoL as measured 
by the SF­ 36 at study visit was lower in adults with childhood­ 
Figure 2. Childhood­ onset systemic lupus erythematosus–related damage defined by a Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index score of ≥1. A, Percentage of patients with damage according to organ system. B, Number 
of patients with and without damage, by disease duration category. C, Percentage of cumulative specific organ damage relative to the sum of 
damage scores in all organ systems, displayed by disease duration category. DM = diabetes mellitus.
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onset SLE in 6 of the 8 assessed domains when compared 
to the Dutch population (Figure  3A). Low disease activity, 
defined as a  SLEDAI score of ≤4, positively affected HRQoL 
(Figure  3B). A more detailed evaluation of SLEDAI­ 2K items 
concerning changes in physical appearance (e.g., ongoing 
inflammatory rash and/or alopecia [n = 25]) revealed a clearly 
negative impact on HRQoL in 7 of 8 domains (Figure  3C). 
Notably, HRQoL scores in these patients were similar to or 
even lower than those of patients with high disease activ­
ity (SLEDAI­ 2K ≥8), even though only 24% of patients with 
changes in physical appearance had high disease activity. 
An active renal component as defined by the SLEDAI­ 2K (n 
= 14) did not affect HRQoL. No differences in HRQoL scores 
were observed between white and nonwhite patients (data not 
shown). Notably, in 7 of the 8 domains, HRQoL scores did not 
differ between patients with damage and those without; sig­
nificantly lower scores in patients with damage were observed 
only in the physical functioning domain (Figure 3D). Addition­
ally, physical functioning domain scores of patients with very 
long disease durations (>30 years) were worse compared to 
those of patients with short disease durations (<10 years). On 
the other hand, mental health domain scores improved over 
time, with higher scores in patients with a long disease dura­
tion (data not shown).
Table 2. Binary logistic regression analysis of variables associated with damage as the outcome measure* 
Predictor (no. of patients)
 Univariate analysis Multivariate analysis
β† OR (95% CI) P β† OR (95% CI) P
Disease duration (111)  0.107 1.113 (1.057–1.171) <0.001  0.139 1.147 (1.077–1.227) <0.001
No. of ACR criteria elements met at 
diagnosis (111)
 0.036 1.037 (0.786–1.367)  0.798 – – –
Age at diagnosis (111) −0.70 0.933 (0.811–1.072)  0.322 – – –
Use of DMARDs/glucocorticoids with or 
without HCQ (75)
Compared to HCQ monotherapy (22) −1.259 0.283 (0.103–0.776)  0.014 −1.818 0.162 (0.042–0.633)  0.009
Compared to no HCQ, glucocorticoids, 
or non- HCQ DMARDs (14)
−0.185 0.831 (0.251–2.747) 0.761 −0.942 0.390 (0.085–1.787)  0.225
White (80) compared to nonwhite (31)  0.754 2.215 (0.847–5.329)  0.108‡ – – –
Female (101) compared to male (10) −0.964 0.381 (0.077–1.888)  0.237‡ – – –
aPL negativity (44) 
Compared to aPL positivity (48)  0.990 2.692 (1.130–6.417)  0.025  1.269 3.559 (1.161–10.908) 0.026
Compared to unknown aPL status (19)  0.539 1.714 (0.569–5.169)  0.338  0.264 1.302 (0.333–5.092)  0.704
No renal involvement ever (44) –
Compared to renal involvement within 2 
years of diagnosis (50)
 0.663 1.94 (0.839–4.490)  0.121‡ – –
Compared to renal involvement after 2 
years (17)
 0.784 2.191 (0.660–7.268)  0.200‡
No CNS involvement ever (78)
Compared to CNS involvement within 2 
years of diagnosis (9)
1.023 7.515 (1.595–35.423) 0.214‡
Compared to CNS involvement after 2 
years of diagnosis (24)
0.266 2.088 (0.826–5.276) 0.591‡
Nephrotic syndrome (24) compared to 
no nephrotic syndrome ever (87) 
 1.738 5.687 
(1.578–20.488)
 0.008  0.932 –  0.242§
Hospitalization (50) compared to no 
hospitalization due to infection ever 
(61)
 0.505 1.656 (1.098–2.500)  0.016  0.393 –  0.456§
Hypertension (71) compared to no 
hypertension ever (40) 
 1.522 4.583 (1.792–11.715)  0.001  1.167 3.214 (1.040–9.932) 0.043
* OR = odds ratio; 95% CI = 95% confidence interval; ACR = American College of Rheumatology; DMARDs = disease- modifying antirheumatic 
drugs; HCQ = hydroxychloroquine; aPL = antiphospholipid antibody; CNS = central nervous system. 
† Regression coefficient. 
‡ A cutoff of P <0.100 was set to select the variables for multivariate logistic regression. As such, these covariates were not incorporated in 
the multivariate model. 
§ These covariates did not improve the fit of the model and were therefore not used for the final multivariate model. 
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DISCUSSION
This is the first study to report data on disease manifes­
tations over time, damage, and HRQoL in a large cohort of 
predominantly white adult patients with childhood­ onset SLE 
with very long disease duration. Most patients had low dis­
ease activity but still took DMARDs and/or glucocorticoids 20 
years after diagnosis. More than half of the patients also took 
medications to treat noninflammatory disease or damage­ 
related symptoms. Clearly, drug­free remission remains diffi­
cult to achieve, and current DMARDs are not effective enough 
to be taken without glucocorticoids in many patients. Indeed, 
half of the patients in our cohort were still taking glucocorti­
coids with or without DMARDs, which was also reported in 
cohorts that included patients with childhood­ onset SLE or 
adult­ onset SLE patients with a mean disease duration of 
12–16 years (18,19). This is concerning, as glucocorticoids 
are associated with the development of damage (39). Patients 
in the CHILL­ NL cohort were eager to limit glucocorticoid use, 
as nearly all reported negative experiences with prednisone, 
especially with regard to their physical appearance and/or 
mental well­ being. Although our findings may be influenced by 
recall bias, they illustrate the perceived impact of glucocorti­
coid use on a patient’s well­ being, emphasizing the need for 
the development of new treatment strategies that can limit or 
even eliminate glucocorticoid use.
Most organ systems became involved within the first 2 years 
of diagnosis, and thereafter hardly any new childhood­ onset SLE–
related manifestations occurred in organ systems not previously 
affected. This finding was also reported in 2 childhood­ onset SLE 
cohorts, but these cohorts had a mean disease duration of only 
4 years (32,40). After 5 years of disease, our study demonstrated 
that the nature of disease manifestations shifts to damage (such 
as myocardial infarction) instead of primary disease–related man­
ifestations (such as pericarditis or epilepsy). This shift has also 
been observed in adult­ onset SLE patients (41–44), and there 
has been a push for preventative screening measures for cardi­
ovascular damage and healthy lifestyle advice (i.e., guidance on 
healthy diet, regular exercise, abstinence from smoking). A study 
that examined laboratory markers of cardiovascular risk in ado­
lescents with childhood­ onset SLE showed that disease duration 
and signs of renal injury (e.g., proteinuria, history of hypertension) 
Figure 3. Health­ related quality of life expressed as mean Short Form 36 (SF­ 36) health survey scores per domain. Spidergrams (63) show 
mean scores within each domain of the SF­ 36, ranging from 0 (worst) to 100 (best). A, SF­ 36 scores of childhood­ onset systemic lupus 
erythematosus (SLE) patients versus those of the overall Dutch population. B, SF­ 36 scores of patients with low SLE Disease Activity Index 
2000 (SLEDAI­ 2K) scores (≤4), intermediate scores (5–7), and high scores (≥8). C, SF­ 36 scores of patients with affirmative responses to 
questions about effects on physical appearance (e.g., ongoing inflammatory rash and/or alopecia) versus patients without these symptoms and 
patients with SLEDAI­ 2K scores ≥8. D, SF­ 36 scores of patients with damage (Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage Index [SDI] score ≥1) versus patients without damage (SDI score 0). GH = general health perception domain; 
PF = physical functioning domain; RP = role limitations due to physical problems domain; BP = bodily pain domain; VT = vitality domain; MH = 
mental health domain; RE = role limitations due to emotional problems domain; SF = social functioning domain. * = P < 0.05. Color figure can 
be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40697/abstract.
GROOT ET AL 298    |
were associated with these markers (45). As has also been shown 
by others (12,18), we found in the present study that cardiovas­
cular damage begins when childhood­ onset SLE patients are in 
their 20s and early 30s, so prevention strategies must be con­
sidered during transition to adult care, especially in patients with 
renal involvement. Because infections are common and related to 
mortality in childhood­ onset SLE patients (46,47), infection pre­
vention by vaccination should be encouraged (48,49).
The majority of our patients had developed damage by their 
mid­ 20s, and this percentage increased with longer disease dura­
tion. The musculoskeletal system, kidneys, and CNS were the 
most frequently affected, as in other childhood­ onset SLE stud­
ies, though those studies involved patients with limited disease 
duration (5–10 years) (13,15,16,19,50). The only available studies 
of damage in patients with a mean disease duration of ≥20 years 
were performed in adult­ onset SLE (50,51). Reported frequency 
and characteristics of damage in these cohorts were similar to the 
results in the CHILL­ NL cohort. However, the mean age at diag­
nosis in the adult­ onset SLE cohorts was 31 years (50,51), ver­
sus 14 years in our study, which likely explains why most patients 
with childhood­ onset SLE began to develop significant damage in 
their early 20s. This is further supported by reports from 2 North 
American childhood­ onset SLE cohorts (mean disease durations 
of 5 years and 16.5 years) that described myocardial infarction in 
childhood­ onset SLE patients in their 20s and 30s (12,18).
Disease duration was the main variable associated with 
the development of damage in the CHILL­ NL cohort, followed 
by aPL positivity and hypertension (Table 2), and this has been 
 consistently demonstrated in many other childhood­ onset SLE 
studies (13,15,50–53). Presence of damage did not differ between 
white and nonwhite patients in our study, but other studies have 
shown conflicting results regarding ethnicity and development of 
damage (7,9,12). Similar socioeconomic status among white and 
nonwhite patients could possibly explain the lack of association 
of ethnicity with damage (7–11). Due to the low number of men 
included, this study was underpowered to assess associations of 
sex with damage.
Current HCQ monotherapy was associated with the absence 
of damage, although no information regarding the duration of 
HCQ monotherapy was recorded. Therefore, we cannot be sure 
of a causal relationship between current HCQ monotherapy and 
mild disease. This is further highlighted by the lack of association 
of organ involvement and antiinflammatory medication use (ever) 
between the patients currently receiving HCQ monotherapy and 
other patients. Longitudinal cohort studies are necessary to fur­
ther clarify this issue.
Notably, the association of damage with disease duration 
also reflects past and current treatment modalities. Patients with 
long disease duration may have developed more damage over 
time due to treatment strategies that are now uncommon, and 
more recently diagnosed patients may have had the benefit of 
improved treatment strategies that led to less damage. The cross­ 
sectional design of this study does not allow us to isolate the pos­
itive effects of improved treatment modalities from the negative 
effects of disease duration on the development of damage.
This is the first study assessing HRQoL in childhood­ onset SLE 
patients after they have reached adulthood. HRQoL was reduced 
in most domains when compared to the overall Dutch population. 
Other studies in children with childhood­ onset SLE and adult­ onset 
SLE patients also showed that patients had an impaired HRQoL 
(21,54–56), and HRQoL scores were similar or even lower when 
compared to patients with other chronic illnesses (54–57). A possi­
ble explanation for the similar mental and emotional health scores 
of the CHILL­ NL cohort as compared to those of the overall Dutch 
population (Figure 3) might be the development of resilience at a 
young age to the emotional impact of the disease, as perceived 
HRQoL can be affected by different styles of coping (58).
High disease activity (SLEDAI­ 2K ≥8) had a significant negative 
effect on HRQoL, which is supported by other studies (20,21,57,59). 
Interestingly, an even larger negative effect was seen with regard 
to factors affecting physical appearance. Indeed, 2 other studies 
showed that changes in physical appearance (e.g., obesity, skin 
involvement) were associated with reduced HRQoL (60,61). Sur­
prisingly, in the CHILL­ NL cohort, the presence of damage barely 
affected HRQoL, with only scores in the physical functioning domain 
significantly reduced. However, other studies showed a negative 
association of damage with HRQoL (21,52). This discrepancy might 
be explained by the heterogeneous nature of damage that can differ 
between cohorts, but also by the development of coping styles in 
childhood­ onset SLE patients, who may have learned at an earlier 
age to adjust their lifestyle according to damage.
The CHILL­ NL study has several strengths. It is a large 
cohort, and all patients were seen in person, providing the oppor­
tunity to verify disease activity and damage by laboratory analysis 
and physical examination. Medical records were retrieved for all 
patients, by which all reported outcomes were verified. The lack 
of studies in adults with childhood­ onset SLE demonstrates the 
challenge in identifying patients after they transfer to adult care. 
Even in a report from a North American cohort that included out­
comes in adult childhood­ onset SLE patients, the study was not 
designed to specifically recruit adults with childhood­ onset SLE 
(62). The present study describes verified disease characteristics 
and HRQoL in the largest cohort of childhood­ onset SLE patients 
with very long disease duration.
The limitations of the CHILL­ NL study must also be 
addressed. First, the number of patients who were not interested 
in participating in the study (and as such were not referred to the 
study team) was unknown. It must be noted that the patients 
included in this study are not a random selection of the total 
childhood­ onset SLE population in The Netherlands. Patients 
from both ends of the severity spectrum (i.e. those with severe 
disease and those with mild disease) who do not visit a physi­
cian regularly will be missed in this cross­ sectional study. Patients 
with high disease activity or severe damage may not have partic­
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ipated in the study due to participation being seen as too taxing. 
To overcome this limitation, we offered to travel to the patient if 
they indicated that travel distance was seen as a barrier. Of the 
patients who were referred to the study team, the vast major­
ity participated in the study. Second, due to the cross­ sectional 
nature of the study, deceased patients were not included. As 
disease severity is a risk factor for mortality (11,50), it is possi­
ble that our study had a bias toward less severe disease. Third, 
data for this study were collected retrospectively, and information 
may have been missed. We chose only to report disease char­
acteristics that could be verified with medical records, and no 
data could be collected from deceased patients. Consequently, 
it is likely that the results from the CHILL­ NL study will under­
represent the severity of the disease. These limitations illustrate 
the need for longitudinal cohorts in which childhood­ onset SLE 
patients are followed up even after they transfer to adult care (12).
In conclusion, the CHILL­ NL study shows that childhood­ 
onset SLE has a major impact on adult life. This is the first 
study to provide insight into the HRQoL and the development 
of disease manifestations and damage over time in adults with 
childhood­ onset SLE. Childhood­ onset SLE–related manifesta­
tions developed mostly within 2 years of diagnosis, with a shift to 
development of damage 5 years after diagnosis. Major medical 
complications (i.e., renal transplants, CVA, myocardial infarction) 
occurred at a young age. These results demonstrate the need for 
optimal control over disease activity and preventative screening 
measures (particularly cardiovascular) beginning before age 30 to 
facilitate a better disease prognosis. HRQoL scores of adults with 
childhood­ onset SLE are affected by factors other than disease 
activity or damage alone. By identifying and addressing these fac­
tors, such as physical appearance and coping styles, HRQoL may 
be improved.
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